复方肾复片治疗IgA肾病32例  

Compound Shenfu Tablets in the Treatment of 32 cases of IgA Nephropathy

作　　者：刘春莹[1] 任艳芸[1] 冷伟[1] 陈磊鑫[2] 

机构地区：[1]陕西中医学院附属医院肾内科,陕西咸阳712000 [2]陕西中医学院,2009级研究生陕西咸阳712046

出　　处：《现代中医药》2010年第6期50-52,共3页Modern Chinese Medicine

基　　金：咸阳市科技局2008年资助项目[XK0816-2(4)]

摘　　要：目的探讨中药复方肾复片对IgA肾病患者蛋白尿及肾损害的治疗效果。方法取本院门诊及住院患者61例,随机分为治疗组32例和对照组29例,基础治疗之上,治疗组加服复方肾复片,对照组加服贝那普利。疗程12W,观察24 h尿蛋白定量、血清尿素氮、血清肌酐、中医证候积分等疗效指标。结果疗程结束后治疗组24-UP下降显著,与对照组相比差异显著(P<0.01);治疗后两组中医证候积分治疗组下降显著(P<0.01);两组血肌酐、尿素氮均无明显变化;总体临床疗效比较发现,治疗组有效率明显高于对照组(P<0.05)。观察过程中两药均未发生严重不良反应。结论复方肾复片可以明显降低IgA肾病气虚伴湿、瘀证患者的蛋白尿,明显改善临床症状、中医证候积分,无严重不良反应。Objective To investigate the therapeutic effect of compound Shenfu tablets on proteinuria and kidney injury of patients with IgA nephropathy. Method 61 cases of out and in patients were randomized into the therapeutic group （32 cases） and the control group （29 cases ）. Besides the basic therapy, the therapeutic group was supplemented with compound Shenfu tablets, and the control group with benazepril. The treatment course was 12 weeks, 24h proteinuria excretion, serum urea nitrogen （SUN）, serum ereatinine （SCR） and TCM syndrome score were observed. Results After the treatment 24 - UP of the therapeutic group lowered markedly, and the difference was significant compared with the control group （ P 〈 0.01 ） ; TCM syndrome scores of both groups decreased obviously （ P 〈 0.01 ） ; SUN and SCR of both groups had no obvious change ; the total clinical reactions of the therapeutic group was greatly better than that of the control group （P 〈 0.05 ）. No severe adverse reactions were observed in either medicine during the course. Conclusion Compound Shenfu tablets can lower proteinuria excretion in IgA nephropathy patients with qi deficiency, dampness and stasis syndromes. The clinical symptoms and TCM syndrome score can be improved significantly and no severe adverse reactions.

关 键 词：IGA肾病 蛋白尿 中医证候积分 复方肾复片 

分 类 号：R692[医药卫生—泌尿科学]